- Home
- VSTM vs CTMX Comparison
VSTM vs CTMX Comparison
Compare VSTM & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- CTMX
- Stock Information
- Founded
- VSTM 2010
- CTMX 2008
- Country
- VSTM United States
- CTMX United States
- Employees
- VSTM N/A
- CTMX N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- VSTM Health Care
- CTMX Health Care
- Exchange
- VSTM Nasdaq
- CTMX Nasdaq
- Market Cap
- VSTM 581.6M
- CTMX 596.2M
- IPO Year
- VSTM 2012
- CTMX 2015
- Fundamental
- Price
- VSTM $8.00
- CTMX $3.61
- Analyst Decision
- VSTM Strong Buy
- CTMX Strong Buy
- Analyst Count
- VSTM 9
- CTMX 5
- Target Price
- VSTM $13.38
- CTMX $5.80
- AVG Volume (30 Days)
- VSTM 2.9M
- CTMX 3.5M
- Earning Date
- VSTM 11-04-2025
- CTMX 11-06-2025
- Dividend Yield
- VSTM N/A
- CTMX N/A
- EPS Growth
- VSTM N/A
- CTMX 50.22
- EPS
- VSTM N/A
- CTMX 0.24
- Revenue
- VSTM $13,379,000.00
- CTMX $113,631,000.00
- Revenue This Year
- VSTM $88.60
- CTMX N/A
- Revenue Next Year
- VSTM $416.99
- CTMX N/A
- P/E Ratio
- VSTM N/A
- CTMX $15.11
- Revenue Growth
- VSTM 33.79
- CTMX N/A
- 52 Week Low
- VSTM $3.46
- CTMX $0.40
- 52 Week High
- VSTM $11.25
- CTMX $4.62
- Technical
- Relative Strength Index (RSI)
- VSTM 43.46
- CTMX 51.22
- Support Level
- VSTM $7.55
- CTMX $3.22
- Resistance Level
- VSTM $10.09
- CTMX $4.62
- Average True Range (ATR)
- VSTM 0.64
- CTMX 0.33
- MACD
- VSTM -0.09
- CTMX 0.01
- Stochastic Oscillator
- VSTM 16.54
- CTMX 19.86
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.